First dose‐ranging study of remimazolam in Japanese patients undergoing gastrointestinal endoscopy: Phase <scp>II</scp> investigator‐initiated clinical trial

Abstract

Initial and additional doses of 3 mg and 1 mg/dose of remimazolam, respectively, were shown to be effective and safe for sedation during gastrointestinal endoscopy in Japanese patients.